[go: up one dir, main page]

PE20090998A1 - Inhibidores de mapk/erk quinasa - Google Patents

Inhibidores de mapk/erk quinasa

Info

Publication number
PE20090998A1
PE20090998A1 PE2008001910A PE2008001910A PE20090998A1 PE 20090998 A1 PE20090998 A1 PE 20090998A1 PE 2008001910 A PE2008001910 A PE 2008001910A PE 2008001910 A PE2008001910 A PE 2008001910A PE 20090998 A1 PE20090998 A1 PE 20090998A1
Authority
PE
Peru
Prior art keywords
fluoro
iodophenylamine
tetrahydroindolizin
halo
oxo
Prior art date
Application number
PE2008001910A
Other languages
English (en)
Inventor
Mark E Adams
Qing Dong
Stephen W Kaldor
Toufike Kanouni
Nicholas Scorah
Michael B Wallace
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20090998A1 publication Critical patent/PE20090998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE X1 ES CR4 O N, EN DONDE R4 ES H, HALO, ALQUILAMINO(C1-C10), SULFONAMIDO, ENTRE OTROS; X2, X3 Y X4 SON CADA UNO -CR5R6-, -NR7-, -O- O -S-, EN DONDE R5 Y R6 SON CADA UNO H, HALO, NITRO, CN, ENTRE OTROS; R7 ES H, HALO, ALQUILO(C1-C10), IMINOALQUILO(C1-C10), ENTRE OTROS; Y1 E Y2 SON CADA UNO O, S O NR8, EN DONDE R8 ES H, ALQUILO(C1-C10), HIDROXIALQUILO(C1-C10), ENTRE OTROS; R1 ES CICLOALQUILO(C3-C12), ARILO(C4-C12), BICICLOALQUILO(C9-C12), ENTRE OTROS; R2 ES H; R3 ES HIDROXI, AMINO, SULFONAMIDO, IMINO, ENTRE OTROS; n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: ACIDO 6-FLUORO-7-(2-FLUORO-4-IODOFENILAMINO)-5-OXO-1,2,3,5-TETRAHIDROINDOLIZIN-8-CARBOXILICO, (R)-N-(2,3-DIHIDROXIPROPOXI)-6-FLUORO-7-(2-FLUORO-4-IODOFENILAMINO)-5-OXO-1,2,3,5-TETRAHIDROINDOLIZIN-8-CARBOXAMIDA, N-(1,3-DIHIDROXIPROPAN-2-ILOXI)-6-FLUORO-7-(2-FLUORO-4-IODOFENILAMINO)-5-OXO-1,2,3,5-TETRAHIDROINDOLIZIN-8-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS PROTEINA QUINASAS ACTIVADAS POR MITOGENOS (MEK O MAPK/ERK) SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS CANCEROSOS, PANCREATITIS, ASMA, ATEROESCLEROSIS
PE2008001910A 2007-11-12 2008-11-12 Inhibidores de mapk/erk quinasa PE20090998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98727907P 2007-11-12 2007-11-12

Publications (1)

Publication Number Publication Date
PE20090998A1 true PE20090998A1 (es) 2009-08-12

Family

ID=40340592

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001910A PE20090998A1 (es) 2007-11-12 2008-11-12 Inhibidores de mapk/erk quinasa

Country Status (10)

Country Link
US (1) US8022057B2 (es)
EP (1) EP2227469B9 (es)
JP (1) JP5453290B2 (es)
AR (1) AR069462A1 (es)
CA (1) CA2705452C (es)
CL (1) CL2008003366A1 (es)
ES (1) ES2456966T3 (es)
PE (1) PE20090998A1 (es)
TW (1) TW200934775A (es)
WO (1) WO2009064675A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AU2007353385A1 (en) 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
PE20100747A1 (es) * 2008-04-21 2010-11-03 Novartis Ag Compuestos heterociclicos como inhibidores de mek
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
AU2009344690A1 (en) * 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
JP5466767B2 (ja) * 2009-11-04 2014-04-09 ノバルティス アーゲー Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
CN101747300B (zh) * 2009-12-22 2012-11-07 上海大学 基于紫杉醇和氮芥的协同前药及其制备方法
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) * 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
TW201321382A (zh) * 2011-07-27 2013-06-01 Glaxo Group Ltd 化合物
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
FI3702351T3 (fi) 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
JP2015003902A (ja) 2013-05-20 2015-01-08 杏林製薬株式会社 血管新生阻害剤
WO2014204263A1 (en) 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
EP3355923B1 (en) 2015-10-01 2022-02-23 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Histone deacetylase inhibitors for use in the treatment of drug resistant melanoma
WO2017099591A1 (en) 2015-12-07 2017-06-15 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en) 2016-05-24 2017-11-30 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Combination therapy - combined map2k4/map3k1 and mek/erk inhibition
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
SG11202101397TA (en) 2018-08-13 2021-03-30 Beijing Percans Oncology Co Ltd Biomarkers for cancer therapy
CN111662282B (zh) * 2019-03-07 2021-07-06 湖南化工研究院有限公司 氮杂环并吡啶类化合物及其中间体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616916B2 (en) 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
JPH0670044B2 (ja) * 1987-11-20 1994-09-07 キッセイ薬品工業株式会社 ４ｈ―キノリジン―４―オン誘導体
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
WO2003077914A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
ES2331246T3 (es) * 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2004293018B2 (en) 2003-11-19 2010-02-18 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PL2298768T3 (pl) 2004-06-11 2013-03-29 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu
EP1838675A1 (en) 2004-11-24 2007-10-03 Laboratoires Serono S.A. Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders
ATE443063T1 (de) 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
ES2378760T3 (es) 2005-05-18 2012-04-17 Array Biopharma, Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
AU2007353385A1 (en) * 2006-10-23 2008-11-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
EP2113500A1 (en) * 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
PE20100747A1 (es) * 2008-04-21 2010-11-03 Novartis Ag Compuestos heterociclicos como inhibidores de mek
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors

Also Published As

Publication number Publication date
JP5453290B2 (ja) 2014-03-26
US8022057B2 (en) 2011-09-20
EP2227469A1 (en) 2010-09-15
JP2011503099A (ja) 2011-01-27
AR069462A1 (es) 2010-01-27
CA2705452C (en) 2016-05-31
TW200934775A (en) 2009-08-16
CL2008003366A1 (es) 2009-05-29
US20090124595A1 (en) 2009-05-14
CA2705452A1 (en) 2009-05-22
ES2456966T3 (es) 2014-04-24
EP2227469B9 (en) 2014-09-10
WO2009064675A1 (en) 2009-05-22
EP2227469B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
PE20090998A1 (es) Inhibidores de mapk/erk quinasa
ECSP099525A (es) Inhibidores de mek
PE20080972A1 (es) Inhibidores de rho cinasa
PE20120370A1 (es) Derivados de 2,4-diaminopirimidinas como inhibidores de ptk2
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
NZ607794A (en) N-acylsulfonamide apoptosis promoters
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR072471A1 (es) BENZOXACINAS Y BENZOTIACINAS CON ACTIVIDAD INHIBIDORA DE NOS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO EN EL TRATAMIENTO DEL DOLOR.
PE20080319A1 (es) Dihidrotienopirimidinas como agentes inhibidores de pde-4
PE20130647A1 (es) Indoles
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
ATE432272T1 (de) Aminophenylderivate als neue inhibitoren von histondeacetylase
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201792052A1 (ru) Соли амидов n-(1,3,4-оксадиазол-2-ил)арил карбоновой кислоты и их применение в качестве гербицидов
PE20081468A1 (es) Derivados de tetrahidropirimidin-5-carboxamida como inhibidores de mapk/erk quinasa
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
NO20084186L (no) Nye aminer
PE20160886A1 (es) Inhibidores de serina/treonina cinasa

Legal Events

Date Code Title Description
FD Application declared void or lapsed